Drug Trial Radar · NCT06100627
A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jan 11, 2024
Primary completion
Feb 8, 2024
Study completion Feb 28, 2024
Sponsor
- Lead sponsor
- Alebund Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, parallel-group, phase 1 study to evaluate the PD effect of AP301 capsule in healthy volunteers. The study is planned to have 4 treatment arms: Arm 1: 2.10 g/day; arm 2: 4.20 g/day; arm 3: 6.30 g/day; arm 4: 8.40 g/day.
Conditions
- Healthy Subjects
Interventions
AP301Drug
Orally administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urinary phosphorus excretion during AP301 administrationTime frame: From the Day 1 to Day 4 after dosing, assessed up to 3 days
- Effect of AP301 on urinary phosphorus excretionTime frame: From Day -3 to Day 4 after dosing, assessed up to 6 days
- Urinary calcium excretion during AP301 administrationTime frame: From the Day 1 to Day 4 after dosing, assessed up to 3 days
- Effect of AP301 on urinary calcium excretionTime frame: From Day -3 to Day 4 after dosing, assessed up to 6 days
- Effect of AP301 on serum phosphorus and calciumTime frame: From Day -3 to Day 4 after dosing, assessed up to 6 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.